Neuren Pharmaceuticals Ltd (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Ltd (ASX: NEU)
Latest News
Share Market News
Where to invest $10,000 in ASX 200 shares in July
Broker Notes
3 of the best ASX 200 stocks to buy in FY25
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Here are the top 10 ASX 200 shares today
Opinions
3 reasons to be positive on ASX 200 shares in FY25 (and 3 to be wary)
Healthcare Shares
This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!
Broker Notes
These ASX shares could rise 25% to 35%
Share Fallers
Why Cettire, Neuren, Peter Warren, and Qantas shares are falling today
Healthcare Shares
Which ASX biotech shares are pioneering the future of medicine?
Healthcare Shares
This ASX 200 stock can rocket to a record high: Broker
Share Market News
5 things to watch on the ASX 200 on Tuesday
Share Gainers
Here are the top 10 ASX 200 shares today
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Ltd
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
NEU Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 01 Jul 2024 | $20.21 | $-1.06 | -4.98% | 315,587 | $20.98 | $21.06 | $20.14 |
| 28 Jun 2024 | $21.27 | $0.65 | 3.15% | 389,765 | $20.84 | $21.56 | $20.76 |
| 27 Jun 2024 | $20.62 | $-0.24 | -1.15% | 232,164 | $20.45 | $20.62 | $20.26 |
| 26 Jun 2024 | $20.86 | $0.64 | 3.17% | 448,162 | $20.45 | $21.10 | $20.39 |
| 25 Jun 2024 | $20.22 | $0.24 | 1.20% | 441,304 | $20.11 | $20.34 | $19.63 |
| 24 Jun 2024 | $19.98 | $-0.02 | -0.10% | 253,855 | $20.05 | $20.28 | $19.82 |
| 21 Jun 2024 | $20.00 | $0.09 | 0.45% | 591,493 | $19.88 | $20.07 | $19.73 |
| 20 Jun 2024 | $19.91 | $-0.03 | -0.15% | 417,369 | $19.95 | $20.00 | $19.50 |
| 19 Jun 2024 | $19.94 | $-0.04 | -0.20% | 240,790 | $19.92 | $20.04 | $19.51 |
| 18 Jun 2024 | $19.98 | $0.18 | 0.91% | 320,620 | $19.95 | $20.18 | $19.59 |
| 17 Jun 2024 | $19.80 | $0.30 | 1.54% | 271,475 | $19.49 | $19.92 | $19.25 |
| 14 Jun 2024 | $19.50 | $0.19 | 0.98% | 374,137 | $19.39 | $19.98 | $19.38 |
| 13 Jun 2024 | $19.31 | $0.49 | 2.60% | 402,851 | $19.14 | $19.43 | $18.88 |
| 12 Jun 2024 | $18.82 | $-0.20 | -1.05% | 380,942 | $18.96 | $19.06 | $18.72 |
| 11 Jun 2024 | $19.02 | $-0.45 | -2.31% | 623,804 | $19.49 | $19.56 | $18.60 |
| 07 Jun 2024 | $19.47 | $0.08 | 0.41% | 488,185 | $19.58 | $19.85 | $19.23 |
| 06 Jun 2024 | $19.39 | $0.05 | 0.26% | 599,508 | $19.60 | $19.65 | $19.00 |
| 05 Jun 2024 | $19.34 | $0.32 | 1.68% | 728,431 | $19.20 | $19.41 | $18.55 |
| 04 Jun 2024 | $19.02 | $-1.25 | -6.17% | 1,034,242 | $20.40 | $20.50 | $18.82 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 11 Jun 2024 | Joseph(Joe) Basile | Buy | 5,000 | $97,450 |
On-market trade.
|
| 13 Sep 2023 | Joseph(Joe) Basile | Buy | 5,000 | $59,950 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Trevor D Scott | Non-Executive Director | Mar 2002 |
Dr Scott is the founder of T.D. Scott and Co., an accountancy and consulting firm, which he formed in 1988. He is an advisor to companies across industries. Trevor serves on corporate boards and is chairman of several.
|
| Ms Dianne Margaret Angus | Non-Executive Director | Jul 2018 |
Mr Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. Dianne has created global industry partnerships to yield medical, pharmaceutical and agricultural products. She has also driven the path for novel neurological pre-clinical agents to late-stage clinical assets before the FDA and European regulators. With over twenty five years' experience in ASX and NASDAQ listed companies, she has expertise in business development, capital raising and investor relations together with corporate governance and compliance capabilities. She is also a council member of Deakin University.
|
| Mr Jonathan (Jon) Charles Pilcher | Chief Executive OfficerManaging Director | Aug 2013 |
Mr Pilcher was a member of the leadership team at Acrux throughout a period that included Acrux's IPO and listing on the ASX, the development and FDA approval of three novel pharmaceutical products and a transforming licensing deal with Eli Lilly in 2010. He formerly spent seven years in a series of executive positions in the R&D and corporate functions of international pharmaceutical groups Medeva and Celltech, which are now part of UCB.
|
| Dr Jenny Lee Harry | Non-Executive Director | Jul 2018 |
Dr Harry has 20 years' experience in executive management of companies in the biotechnology and biopharmaceutical industry. Jenny is a CEO and Managing Director with experience in growing companies from start-up to commercialisation. She has served on Board's of listed and unlisted companies and on the Board's IP sub-committee of the Children's Medical Research Institute.
|
| Mr Patrick Davies | Non-Executive DirectorNon-Executive Chairman | Jul 2018 |
Mr Davies has held executive management roles in the Australian and New Zealand healthcare industry for over twenty five years having performed in roles across industry sectors including pharmacy, primary care, pharmaceutical and consumer products. During his ten year period as Chief Executive Officer of EBOS Group Limited (and previously Symbion), the enterprise value of the group achieved compound annual growth in enterprise value of +20% (from circa $450M to in excess of $3.1B). He is a director on other corporate boards and provides advice to healthcare businesses and investors.
|
| Mr Joseph(Joe) Basile | Non-Executive Director | Mar 2023 |
Mr Basile has held executive roles in the pharmaceutical industry for over 30 years, most recently as Group CFO at iNova Pharmaceuticals based in Singapore and prior to that with Novartis in senior Finance leadership and Commercial Sales roles in Australia and Asia.
|
| Ms Lauren Frazer | Chief Financial OfficerCompany Secretary | Aug 2020 |
-
|
| Lauren Frazer | Chief Financial OfficerCompany Secretary |
-
|
|
| Liza Squires | Chief Medical Officerf |
-
|
|
| Larry Glass | Chief Science Officer |
-
|
|
| Gerry Zhao | Vice President Corporate Development |
-
|
|
| Clive Blower | Vice President Product Development |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 22,507,287 | 17.65% |
| J P Morgan Nominees Australia Pty Limited | 12,099,419 | 9.49% |
| Citicorp Nominees Pty Limited | 11,687,108 | 9.17% |
| National Nominees Limited | 4,166,698 | 3.27% |
| Cameron Richard Pty Ltd | 4,123,084 | 3.23% |
| Bnp Paribas Noms Pty Ltd | 3,584,206 | 2.81% |
| Stuart Andrew Pty Ltd | 2,633,787 | 2.07% |
| Essex Castle Limited | 2,387,678 | 1.87% |
| Smithley Super Pty Ltd | 1,870,000 | 1.47% |
| Linwierik Super Pty Ltd | 1,761,385 | 1.38% |
| Sharesies Australia Nominee Pty Limited | 1,435,555 | 1.13% |
| Bnp Paribas Nominees Pty Ltd | 796,367 | 0.62% |
| First Colbyco Pty Ltd | 750,000 | 0.59% |
| Mjhft Pty Ltd | 750,000 | 0.59% |
| Bnp Paribas Nominees Pty Ltd Acf Clearstream | 745,279 | 0.58% |
| Dr Robin Lance Congreve | 671,637 | 0.53% |
| Hsbc Custody Nominees (Australia) Limited A/C 2 | 499,399 | 0.39% |
| Emancipayte Pty Ltd | 470,756 | 0.37% |
| Netwealth Investments Limited | 421,309 | 0.33% |
| Mr He Zhao | 405,000 | 0.32% |
| Pfizer Inc | 404,072 | 0.32% |
